LCG
AERI

Lisanti Capital Growth’s Aerie Pharmaceuticals AERI Stock Holding History

Lisanti Capital Growth’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,740
Closed -$215K – 129
2017
Q1 		$215K Buy
+4,740
New +$211K 0.31% 88

Other funds holding AERI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Lisanti Capital Growth's AERI Position: Q2 2017 in Review

Lisanti Capital Growth sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 4,740 shares — an estimated $215K sold.

Lisanti Capital Growth first reported a position in AERI in Q1 2017 and held it in 1 quarter. The position peaked at $215K in Q1 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

  • Lisanti Capital Growth reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Lisanti Capital Growth sold 4,740 Aerie Pharmaceuticals shares in Q2 2017, an estimated $215K.
  • Lisanti Capital Growth first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Lisanti Capital Growth's Aerie Pharmaceuticals position peaked at $215K in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Lisanti Capital Growth's 13F filing for Q2 2017, filed 28 Jul 2017.